LOGIN  |  REGISTER
Viking Therapeutics

ICU Medical Issues Nationwide Recall of POTASSIUM CHLORIDE INJECTION, 20 mEq and POTASSIUM CHLORIDE INJECTION, 10 mEq Due to Mislabeling

February 13, 2025 | Last Trade: US$140.54 2.11 -1.48

LAKE FOREST, Ill., Feb. 13, 2025 /PRNewswire/ -- ICU Medical, Inc. is voluntarily recalling one lot each of POTASSIUM CHLORIDE Inj. bags with overwrap labels 10 mEq, packaged in cases of POTASSIUM CHLORIDE Inj. 20 mEq, to the user level. ICU Medical has received a customer complaint which states that bags of POTASSIUM CHLORIDE Inj. 20 mEq have incorrect overwrap labels which state POTASSIUM CHLORIDE Inj. 10 mEq.

Example Case Label

ICU Medical has identified a potential for some of the product overwraps in one lot being mislabeled as 10 mEq (instead of 20 mEq that is contained in the I.V. Bag) of POTASSIUM CHLORIDE due to a manufacturing issue. The 20 mEq, correctly printed on the labeling affixed to the bag, is not visible or not easily visible without manipulation when the 10 mEq overwrap is in place.

Risk Statement: If the Health Care provider mistakenly calculates the patient dose using 10 mEq, the patient will receive an overdose of potassium chloride. Severe hyperkalemia after large intravenous overdoses causes neuromuscular dysfunction including muscle weakness, ascending paralysis, listlessness, vertigo, mental confusion, hypotension, cardiac dysrhythmias, or death from cardiac arrest. Premature infants, patients on chronic parenteral nutrition, patients who have a history of cardiac arrythmias, patients with chronic renal insufficiency, patients who have acute renal failure, patients on potassium-sparing diuretics—all are at risk for adverse and potentially fatal outcomes. ICU Medical has not received reports of adverse events associated with this issue to date.

Potassium Chloride Injection 20 mEq and 10 mEq, is indicated in the treatment of potassium deficiency states, when oral replacement is not feasible and is packaged in 100 mL bags. The mislabeled POTASSIUM CHLORIDE Inj. 20 mEq, 100 mL bags contain incorrect overwrap labels with the following information: NDC 0990-7074-26, 200 mEq/L POTASSIUM CHLORIDE Inj. 10 mEq. The lot 1023172 and Exp. Date 31 January 2026 is found on the primary container (see picture). These mislabeled bags are packaged in cases labeled: NDC 0990-7075-26, CASE PACK 1x24 – 100ML 20MEQ POTASSIUM CHLORIDE INJECTION LOT NO. 1023172, EXP DATE 2026-01.  

DESCRIPTION OF MISLABELED BAGS BEING RECALLED:

NDC Number

Barcode Number

Product
Overwrap
Description

Product
Primary Bag
Description

Lot
Number

Expiration
Date

Configuration

0990-7074-26

(01)00309907074269

POTASSIUM
CHLORIDE Inj.
10 mEq

POTASSIUM
CHLORIDE Inj.
20 mEq

1023172

31 January
2026

100 mL
Flexible
Container

0990-7075-26

(01)00309907075266

POTASSIUM
CHLORIDE Inj.
20 mEq

POTASSIUM
CHLORIDE Inj.
20 mEq

1023172

31 January
2026

100 mL
Flexible
Container

DESCRIPTION OF CASES BEING RECALLED:

NDC Number

Barcode Number

Lot Number

Expiration Date

Configuration

0990-7075-26

(01)30309907075267

1023172

31 January 2026

1 x 24 – 100 mL

ICU Medical is notifying its customers, including distributors, of this recall by letter, and is arranging for the return of all recalled product. All Health Care professionals that have product that is being recalled should stop use/further distribution, as applicable, and return to place of purchase.

Consumers with questions regarding this recall can contact ICU Medical by phone number or e-mail address as indicated in the table below.  Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

For further inquiries, please contact ICU Medical using the information provided below.

ICU Medical Contact

Contact Information

Areas of Support

Global Complaint Management

1-844-654-7780 or
This email address is being protected from spambots. You need JavaScript enabled to view it.
M-F 8-5 CST

To report product complaints

Drug Safety

1-844-654-7780 or
This email address is being protected from spambots. You need JavaScript enabled to view it.
M-F 8-5 CST

To report adverse events for IV
Solutions & Drugs

Medical Information

1-800-241-4002, option 6 or
This email address is being protected from spambots. You need JavaScript enabled to view it.
M-F 8-5 CST

Medical inquiries

Customer Care

1-877-946-7747, option 1 M-F 7-6 CST

Product Replacement Options

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Contact:
Consumers
ICU Medical, Inc.
1-844-654-7780

Media Contact:
Harrison Richards
ICU Medical, Inc.
949-366-4261    
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Mislabeled Overwrap

Incorrect Overwrap

Correct Overwrap

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page